866-997-4948(US-Canada Toll Free)

Nasopharyngeal Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Cancer

No. of Pages : 84 Pages


Global Markets Directs, \'Nasopharyngeal Cancer Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Nasopharyngeal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer. 

Nasopharyngeal Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Nasopharyngeal Cancer.
  • A review of the Nasopharyngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Nasopharyngeal Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy


  • Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Nasopharyngeal Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Nasopharyngeal Cancer 10
Nasopharyngeal Cancer Therapeutics under Development by Companies 12
Nasopharyngeal Cancer Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Nasopharyngeal Cancer Therapeutics - Products under Development by Companies 20
Nasopharyngeal Cancer Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Nasopharyngeal Cancer Therapeutics Development 23
Sanofi-Aventis 23
YM BioSciences Inc. 24
Cyclacel Pharmaceuticals Inc. 25
Jiangsu Hengrui Medicine Co., Ltd. 26
Coridon Pty Ltd 27
Biotech Pharmaceuticals Co., Ltd. 28
Nasopharyngeal Cancer - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
seliciclib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
EBNA-1 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
EBV-Specific T-Lymphocytes - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Taxotere + Cisplatin + Radiation Therapy - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Docetaxel + Cisplatin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
docetaxel + fluorouracil + [cisplatin] + Radiation Therapy - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Docetaxel + Cisplatin + Fluorouracil - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 46
nimotuzumab - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Autologous Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes + [carboplatin]+ [gemcitabine] - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
bevacizumab + [cisplatin] + [fluorouracil] + Radiation Therapy - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
nimotuzumab + [cisplatin] - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
MK-2206 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Famitinib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Famitinib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
MK-2206 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Docetaxel + Cisplatin + Radiation Therapy - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Gemcitabine + Valproic acid + Valganciclovir - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
famitinib + [cisplatin] + Radiation Therapy - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Icotinib + [cisplatin] + [paclitaxel] + Radiation Therapy - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
endostatin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Gemcitabine + Cisplatin + Radiation Therapy - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
DNAzyme Targeting EBVLMP-1 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Epstein Barr Virus Vaccine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Imidazoles - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Nasopharyngeal Cancer Therapeutics - Drug Profile Updates 73
Nasopharyngeal Cancer Therapeutics - Discontinued Products 75
Nasopharyngeal Cancer Therapeutics - Dormant Products 76
Nasopharyngeal Cancer - Product Development Milestones 78
Featured News & Press Releases 78
Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer 78
May 29, 2009: Cyclacel Reports Initial Phase 2 Seliciclib Data In Patients With Nasopharyngeal Carcinoma At 2009 Asco Annual Meeting 79
Apr 21, 2009: Cyclacel & Dartmouth Researchers Reports Novel Mechanism Of Action For Seliciclib At AACR 79
Mar 05, 2009: Cyclacel Announces Phase 1 Data Elucidating Pharmacodynamics & Mechanism Of Action Of Seliciclib In Nasopharyngeal Cancer 80
Oct 07, 2008: Epstein-Barr Virus Protein Contributes to Cancer 81
Aug 28, 2008: CYCLACEL Announces Recommendations Of Data Review Committee For Seliciclib Phase 2b Non-Small Cell Lung Cancer APPRAISE Trial 81
Jun 28, 2007: Cyclacel Pharmaceuticals Announces Results Of Phase II Seliciclib Combination Studies 82

Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84

List of Table


Number of Products Under Development for Nasopharyngeal Cancer, H1 2013 10
Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 12
Number of Products under Investigation by Universities/Institutes, H1 2013 14
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Investigation by Universities/Institutes, H1 2013 21
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 22
Sanofi-Aventis, H1 2013 23
YM BioSciences Inc., H1 2013 24
Cyclacel Pharmaceuticals Inc., H1 2013 25
Jiangsu Hengrui Medicine Co., Ltd., H1 2013 26
Coridon Pty Ltd, H1 2013 27
Biotech Pharmaceuticals Co., Ltd., H1 2013 28
Assessment by Monotherapy Products, H1 2013 29
Assessment by Combination Products, H1 2013 30
Assessment by Stage and Route of Administration, H1 2013 32
Assessment by Stage and Molecule Type, H1 2013 34
Nasopharyngeal Cancer Therapeutics - Drug Profile Updates 73
Nasopharyngeal Cancer Therapeutics - Discontinued Products 75
Nasopharyngeal Cancer Therapeutics - Dormant Products 76
Nasopharyngeal Cancer Therapeutics - Dormant Products (Contd..1) 77

List of Chart


Number of Products under Development for Nasopharyngeal Cancer, H1 2013 10
Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 13
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Discovery and Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 29
Assessment by Combination Products, H1 2013 30
Assessment by Route of Administration, H1 2013 31
Assessment by Stage and Route of Administration, H1 2013 32
Assessment by Molecule Type, H1 2013 33
Assessment by Stage and Molecule Type, H1 2013 34

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *